Company: APXIF
Filing Date: 2025-07-18
Form Type: F-4/A
Source: 0001213900-25-065703
Chunk: 258

Company: APx Acquisition Corp. I
Filing Date: 2025-07-18
Form: F-4/A
Chunk 258
---
 estimated fair value of identifiable net assets/(liabilities) of APx upon closing of the Business Combination could have a material impact on the calculation of the estimated listing fee. APx reported an estimated warrant liability related to its public and private warrants of $1.4million as of December31, 2024 that is included in the calculation of the listing charge of $61.9million included in these pro forma financial statements assuming the Business Combination occurred on December31, 2024. APx reported an estimated warrant liability related to its public and private warrants of $4.7million as of March31, 2025, an increase in the liability of $3.3million as compared to December31, 2024. An increase of $3.3million in the estimated warrant liability as of December31, 2024 would have increased the estimated pro forma listing fee expense by an additional $3.3million for a total charge of $65.2million on a pro forma basis. (5)Heritas Argentina, a subsidiary of OmnigenicsAI, received financing from existing credit facilities after December31, 2024, in the total amount of $178,006 ($81,996 from Bioceres S.A. and $96,010 from CIBIC). The terms of these loan agreements include interest rates of 6.5% per annum, with maturity dates in January 2028. For pro forma purposes, said financings are treated as if they were performed on July 1, 2023. In consequence: •in the Unaudited Pro Forma Combined Statement of Operations for the six -monthperiod ended December31, 2024, accrued interests of these borrowings amounted to $5,801; and •in the Unaudited Pro Forma Combined Statement of Operations for the twelve -monthperiod ended June30, 2024, accrued interests of these borrowings amounted to $11,570; and. •in the Unaudited Pro Forma Combined Statement of Financial Position as of December31, 2024, non -currentfinancial debt amounted to $178,006 (the same effect on cash and cash equivalents considering the cash inflow from said financing). (6)Under the terms of the Business Combination Agreement, after December31, 2024 but prior to the closing of said business combination: (a)The Parent will contribute its financial receivable, including accrued interests as of the contribution date, to its subsidiary, OmnigenicsAI. This rece